Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

NCT04749563 is registered in ClinicalTrials.gov with IGC Pharma, LLC as lead sponsor.

NCT NCT04749563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04749563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Lead sponsor
IGC Pharma, LLC
Phase
Phase 1
Overall status
Completed
Start date
January 11, 2021
Completion date
June 20, 2021
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dementia of alzheimer type